PLAT and androgen insensitivity syndrome: Notably, the ICH risk in the setting of AIS without IV tPA therapy remains low, with mainly small petechial HIs associated with baseline stroke severity (16) but with limited, if any, impact on 3 month functional outcome in the ECASS 1 and 2 trials (17–19).